Minerva Neurosciences, Inc: Minerva Neurosciences Announces

Minerva Neurosciences, Inc: Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous

Related Keywords

Fred Ahlholm , Helen Shik , Remy Luthringer , Minerva Neurosciences , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Nasdaq , Executive Chairman , Chief Executive Officer , Aminerva , Neurosciences , Nnounces , Recommendation , Type , Meeting , Iscuss , Evidence , Roluperidone , Monotherapy , Treatment , Negative , Symptoms , Patients , Schizophrenia , Advance , Potential ,